Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 29.64 points (-0.2%) at 18,195 as of Thursday, Feb. 26, 2015, 3:25 PM ET. The NYSE advances/declines ratio sits at 1,400 issues advancing vs. 1,601 declining with 167 unchanged.

The Chemicals industry as a whole was unchanged today versus the S&P 500, which was down 0.4%. Top gainers within the Chemicals industry included Metabolix ( MBLX), up 20.9%, Synthesis Energy Sys ( SYMX), up 5.3%, Marrone Bio Innovations ( MBII), up 6.2%, China Green Agriculture ( CGA), up 2.9% and Amyris ( AMRS), up 14.5%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Marrone Bio Innovations ( MBII) is one of the companies that pushed the Chemicals industry higher today. Marrone Bio Innovations was up $0.21 (6.2%) to $3.58 on light volume. Throughout the day, 30,129 shares of Marrone Bio Innovations exchanged hands as compared to its average daily volume of 83,000 shares. The stock ranged in a price between $3.35-$3.64 after having opened the day at $3.36 as compared to the previous trading day's close of $3.37.

Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products for the crop protection, water treatment, and other target markets in the United States and internationally. Marrone Bio Innovations has a market cap of $84.9 million and is part of the basic materials sector. Shares are down 6.7% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate Marrone Bio Innovations a buy, no analysts rate it a sell, and 2 rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Marrone Bio Innovations as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

Highlights from TheStreet Ratings analysis on MBII go as follows:

  • MARRONE BIO INNOVTIONS has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. For the next year, the market is expecting a contraction of 86.2% in earnings (-$1.75 versus -$0.94).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Chemicals industry. The net income has significantly decreased by 533.6% when compared to the same quarter one year ago, falling from -$1.64 million to -$10.39 million.
  • MBII, with its decline in revenue, underperformed when compared the industry average of 4.7%. Since the same quarter one year prior, revenues fell by 19.4%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • Compared to other companies in the Chemicals industry and the overall market, MARRONE BIO INNOVTIONS's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 72.87%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 455.55% compared to the year-earlier quarter.

You can view the full analysis from the report here: Marrone Bio Innovations Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Synthesis Energy Sys ( SYMX) was up $0.04 (5.3%) to $0.79 on light volume. Throughout the day, 132,787 shares of Synthesis Energy Sys exchanged hands as compared to its average daily volume of 205,900 shares. The stock ranged in a price between $0.76-$0.81 after having opened the day at $0.76 as compared to the previous trading day's close of $0.75.

Synthesis Energy Systems, Inc., a development stage energy and gasification technology company, provides various proprietary gasification technology systems and solutions to the energy and chemical industries worldwide. Synthesis Energy Sys has a market cap of $54.5 million and is part of the basic materials sector. Shares are down 20.8% year-to-date as of the close of trading on Wednesday. Currently there are no analysts who rate Synthesis Energy Sys a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Synthesis Energy Sys as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on SYMX go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Energy Equipment & Services industry. The net income has significantly decreased by 1683.5% when compared to the same quarter one year ago, falling from -$1.44 million to -$25.59 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Energy Equipment & Services industry and the overall market, SYNTHESIS ENERGY SYSTEMS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 54.44%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 1650.00% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • SYNTHESIS ENERGY SYSTEMS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, SYNTHESIS ENERGY SYSTEMS INC continued to lose money by earning -$0.21 versus -$0.34 in the prior year.
  • The revenue fell significantly faster than the industry average of 12.4%. Since the same quarter one year prior, revenues fell by 34.4%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.

You can view the full analysis from the report here: Synthesis Energy Sys Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Metabolix ( MBLX) was another company that pushed the Chemicals industry higher today. Metabolix was up $0.10 (20.9%) to $0.58 on heavy volume. Throughout the day, 205,555 shares of Metabolix exchanged hands as compared to its average daily volume of 136,200 shares. The stock ranged in a price between $0.49-$0.59 after having opened the day at $0.50 as compared to the previous trading day's close of $0.48.

Metabolix has a market cap of $77.7 million and is part of the basic materials sector. Shares are up 16.9% year-to-date as of the close of trading on Wednesday.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.